Navigation Links
CareFusion Announces 510(k) Clearance and U.S. Launch of New Advanced Electrodiagnostic System
Date:3/20/2012

SAN DIEGO, March 20, 2012 /PRNewswire/ -- CareFusion announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new electrodiagnostic system, known as the Viking on Nicolet® EDX. The EDX system is a multi-modality device for monitoring and testing electrophysiological information from the human nervous and muscular system.

(Logo: http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO)

The new EDX system offers an intuitive, ergonomic platform and clinical automation that enables efficient, high-quality nerve conduction studies (NCS), electromyography (EMG) and evoked potential (EP) testing and intra-operative monitoring (IOM). The strong signal quality, environmental noise suppression capability and artifact rejection feature help reduce examination time, which can enhance patient comfort. 

Designed with input from neurologists and electrodiagnostic technicians, the EDX system also helps improve workflow in busy clinical settings by effectively organizing data into a variety of reporting formats. With the versatile system, clinicians can complete their studies and generate reports with ease, helping to streamline workflow, improve clinician efficiency and lower costs.

"We are excited to bring the Viking on Nicolet EDX system to the U.S. market," said Mary de Sousa, vice president and general manager of the Nicolet business of CareFusion. "The EDX system helps strengthen our market-leading EMG portfolio and ensures clinicians and patients can benefit from the latest advancements in neurological care."

The EDX system will now be available in the United States and many other countries worldwide. The product will also be featured at the CareFusion booth at the American Academy of Neurology conference in New Orleans from April 23-26. Visit CareFusion at booth #801.

About CareFusion
CareFusion (NYSE: CFN) is a global corporation serving the health care industry with products and services that help hospitals measurably improve the safety and quality of care. The company develops market-leading technologies including Alaris® infusion pumps, Pyxis® automated dispensing and patient identification systems, AVEA®, AirLife™ and LTV® series ventilation and respiratory products, ChloraPrep® skin prep products, MedMined® services for data mining surveillance, Nicolet™ neurological monitoring and diagnostic products, V. Mueller® surgical instruments, and an extensive line of products that support interventional medicine. CareFusion employs more than 14,000 people across its global operations. More information may be found at www.carefusion.com.


'/>"/>
SOURCE CareFusion
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. CareFusion Reports First Quarter Fiscal 2012 Results
2. ERT Closes the Acquisition of the Research Services Division of CareFusion Corporation
3. GeoVax Announces Private Placement of $2.2 Million
4. Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer
5. Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications
6. Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine
7. Floridas Leading Fertility Center Announces Successful Baby Delivery via Egg Freezing
8. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
9. Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
10. Proteonomix Announces a Private Placement of $3.8 Million
11. Updated: Life Technologies Announces Fourth Quarter and Fiscal Year 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS ... the addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s US ... absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical applications. ...
(Date:10/11/2017)... CA (PRWEB) , ... October 11, 2017 , ... ... upregulate any gene in its endogenous context, enabling overexpression experiments and avoiding the ... system with small RNA guides is transformative for performing systematic gain-of-function studies. ...
(Date:10/11/2017)... 2017  VMS BioMarketing, a leading provider of patient support ... Nurse Educator (CNE) network, which will launch this week. The ... health care professionals to enhance the patient care experience by ... other health care professionals to help women who have been ... ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
Breaking Biology Technology:
(Date:3/27/2017)... CENTRE, N.Y. , March 27, 2017 /PRNewswire-USNewswire/ ... Healthcare Information and Management Systems Society (HIMSS) Analytics ... Outpatient EMR Adoption Model sm . In addition, ... 12% of U.S. hospitals using an electronic medical ... CHS for its high level of EMR usage ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
(Date:3/23/2017)... Research and Markets has announced the addition ... - Industry Forecast to 2025" report to their offering. ... The Global Vehicle ... around 8.8% over the next decade to reach approximately $14.21 billion ... estimates and forecasts for all the given segments on global as ...
Breaking Biology News(10 mins):